You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
大行評級|花旗:上調信達生物目標價至90港元 指其已進入新階段
格隆匯 07-02 12:34
花旗發表研究報告指,信達生物旗下IBI363(PD-1/IL-2alpha-bias雙特異性抗體融合蛋白產品),獲意見領袖們突顯出良好的數據,及有潛力成爲下一代免疫腫瘤治療(IO)關鍵產品。花旗認爲,信達生物可能帶來更廣範圍、高效、低毒的創新癌症治療,而信達生物維持其2027年實現200億元產品收入的目標,並於2030年推進五項管線資產進入國際多中心臨牀實驗(MRCT)第三期。花旗認爲,信達生物已進入新階段,受強勁商業表現及全球創新驅動,並基於折現現金流(DCF)方法,將其目標價從60港元上調至90港元,維持“買入”評級。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account